Composition kits and methods for performing amplification reactions

• US 7,696,337 B2
• Filed: 08/26/2005
• Issued: 04/13/2010
• Est. Priority Date: 08/27/2004
• Status: Active Grant

• Current Assignee: Gen-Probe Incorporated (Hologic Incorporated)
• Original Assignee: Gen-Probe Incorporated (Hologic Incorporated)
• Inventors: Lam, Wai-Chung, Kolk, Daniel P., Schroder, Astrid R. W., Brentano, Steven T., Livezey, Kristin W., Schroth, Gary P., Becker, Michael M., Nelson, Norman C.
• Primary Examiner(s): Horlick; Kenneth R.
• Assistant Examiner(s): Thomas; David C
• Application Number:
  US11/574,307
• Publication Number:
  US 20070299254A1
• Time in Patent Office: 1,691 Days
• Field of Search: None
• US Class Current: 536/23.1
• CPC Class Codes: C12P 19/34 Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• CPC Class Codes: C12Q 1/6865 Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]
• CPC Class Codes: C12Q 2521/107 RNA dependent DNA polymerase,(i.e. reverse transcriptase)
• CPC Class Codes: C12Q 2521/325 Single stranded exonuclease
• CPC Class Codes: C12Q 2525/143 incorporating a promoter sequence
• CPC Class Codes: C12Q 2525/186 incorporating a non-extendable or blocking moiety
• CPC Class Codes: C12Q 2533/101 Primer extension
• CPC Class Codes: C12Q 2537/163 blocking probe

Abstract

The present invention is directed to novel methods of synthesizing multiple copies of a target nucleic acid sequence which are autocatalytic (i.e., able to cycle automatically without the need to modify reaction conditions such as temperature, pH, or ionic strength and using the product of one cycle in the next one). In particular, the present invention discloses a method of nucleic acid amplification which is robust and efficient, while reducing the appearance of side products. The method uses only one primer, the “priming oligonucleotide,” a 3′blocked promoter oligonucleotide and optionally, a means for terminating a primer extension reaction, to amplify RNA or DNA molecules in vitro, while reducing or eliminating the formation of side products. The method of the present invention minimizes or eliminates the emergence of side products, thus providing a high level of specificity. Furthermore, the appearance of side products can complicate the analysis of the amplification reaction by various molecular detection techniques. The present invention minimizes or eliminates this problem, thus providing an enhanced level of sensitivity.

Claims

1. A kit for use in synthesizing multiple copies of an RNA target sequence contained within a target nucleic acid, the kit comprising:

a priming oligonucleotide which hybridizes to the 3′

-end of the RNA target sequence and primes the synthesis of a first DNA primer extension product complementary to the RNA target sequence;

a cap hybridized to the 3′

-end of the priming oligonucleotide, the cap comprising a base region which is complementary to at least 3 nucleotides at the 3′

-end of the priming oligonucleotide, wherein the 5′

-terminal base of the cap is complementary to the 3′

-terminal base of the priming oligonucleotide, and wherein the cap cannot be extended by a nucleic acid polyerase;

a promoter oligonucleotide comprising a first region which hybridizes to a 3′

-region of the first DNA primer extension product and a second region which is a promoter for an RNA polymerase, the promoter oligonucleotide being modified to prevent the initiation of DNA synthesis therefrom; and

a binding molecule which binds to the target nucleic acid adjacent to or near the 5′

-end of the RNA target sequence,

provided that any oligonucleotide included in the kit which comprises a promoter for an RNA polymerase is modified to prevent the initiation of DNA synthesis therefrom.

2. The kit of claim 1, wherein the priming oligonucleotide does not comprise RNA.

3. The kit of claim 2, wherein the cap is complementary to no more than 8 nucleotides at the 3′

-end of the priming oligonucleotide.

4. The kit of claim 2, wherein the cap prevents non-specific hybridization between the priming oligonucleotide and the promoter oligonucleotide when the cap is hybridized to the priming oligonucleotide.

5. The kit of claim 2, wherein the cap is a capping oligonucleotide modified to include a blocking moiety situated at it 3′

-terminus.

6. The kit of claim 2, wherein the 3′

-end of the cap is covalently attached to the 5′

-end of the priming oligonucleotide, and wherein the cap hybridizes to the 3′

-end of the priming oligonucleotide by forming a loop.

7. The kit of claim 6, wherein the cap is joined to the priming oligonucleotide via a linker region.

8. The kit of claim 7, wherein the linker region comprises at least 5 nucleotides.

9. The kit of claim 7, wherein the linker region comprises at least 5 a basic nucleotides.

10. The kit of claim 1, wherein the priming oligonucleotide does not include a non-hybridizing base region situated 5′

to the base region which hybridizes to the target sequence.

11. The kit of claim 10, wherein a 5′

-region of the priming oligonucleotide includes one or more modifications for increasing the binding affinity of the priming oligonucleotide for the target sequence, and wherein the modifications do not prevent the priming oligonucleotide from being extended in a primer extension reaction.

12. The kit of claim 11, wherein the modifications are spaced at least 15 bases from the 3′

-terminus of the priming oligonucleotide.

13. The kit of claim 1 further comprise a reverse transcriptase having an RNAse H activity.

14. The kit of claim 1 further comprising an enzyme having an RNAse H activity, wherein the enzyme is other than a reverse transcriptase.

15. The kit of claim 1, wherein the binding molecule comprises an oligonucleotide having a blocking moiety situated at its 3′

-terminus to prevent the initiation of DNA synthesis therefrom.

16. The kit of claim 15, wherein the 5′

-end of the oligonucleotide of the binding molecule overlaps the 5′

-end of the first region of the promoter oligonucleotide, and wherein the 5′

-end of the first region has a sufficient number of mismatches with the 5′

-end of the oligonucleotide of the binding molecule to prevent the promoter oligonucleotide from hybridizing to the binding molecule.

17. The kit of claim 15, wherein the binding molecule includes one or more modifications for increasing the binding affinity of the binding molecule for the target nucleic acid.

18. The kit of claim 15, wherein the binding molecule is a terminating oligonucleotide.

19. The kit of claim 18, wherein the 5′

-end of the terminating oligonucleotide is complementary to at least two nucleotides at the 5′

-end of the first region of the promoter oligonucleotide.

20. The kit of claim 18, wherein the 5′

-end of the terminating oligonucleotide is complementary to at least three but no more than ten nucleotides at the 5′

-end of the first region of the promoter oligonucleotide.

21. The kit of claim 15, wherein the binding molecule is a modifying oligonucleotide.

22. The kit of claim 21, wherein the modifying oligonucleotide is a digestion oligonucleotide.

23. The kit of claim 1 further comprising an extender oligonucleotide which hybridizes to the first DNA primer extension product 3′

to the promoter oligonucleotide, wherein the extender oligonucleotide comprises a blocking moiety situated at its 3′

terminus to prevent the initiation of DNA synthesis therefrom.

24. The kit of claim 1, wherein the promoter oligonucleotide further comprises an insertion sequence positioned between or adjacent to the first and second regions, and wherein the presence of the insertion sequence in the promoter oligonucleotide enhances the rate at which the RNA products are formed.

25. The kit of claim 24, wherein the insertion sequence comprises the nucleotide base sequence of SEQ ID NO:

1 or SEQ ID NO;

2.

26. The kit of claim 1, wherein the promoter oligonucleotide is modified to include a blocking moiety situated at its 3′

-terminus.

27. The kit of claim 26, wherein the first region of the promoter oligonucleotide is hybridized to an oligodeoxynucleotide, and wherein the first region comprises a 3′

-region having a sufficient number of contiguous ribonucleotides hybridized to the oligodeoxynucleotide such that the blocking moiety of the promoter oligonucleotide is released in the presence of an enzymatic activity capable of cleaving the region of ribonucleotides.

28. The kit of claim 27, wherein the promoter oligonucleotide comprises the oligodeoxynucleotide.

29. The kit of claim 26, wherein the blocking moiety of the promoter oligonucleotide comprises a substituent selected from the group consisting of:

a modified nucleotide, a nucleotide or a nucleotide sequence having a 3′

-to-5′

orientation, a 3′

alkyl group, a 3′

2′

-dideoxynucleotide, a 3′

cordycepin, a 3′

alkane-diol residue, a 3′

non-nucleotide moiety, a nucleotide sequence non-complementary to the target sequence, a nucleic acid binding protein, and mixtures thereof.

30. The kit of claim 29, wherein the blocking moiety comprises a nucleotide or a nucleotide sequence having a 3′

-to-5′

orientation or a 3′

-non-nucleotide moiety.

31. A kit for use in synthesizing multiple copies of a DNA target sequence contained within a target nucleic acid, the kit comprising:

a promoter oligonucleotide comprising a first region which hybridizes to a 3′

-region of the DNA target sequence present in a target nucleic acid to form a promoter oligonucleotide;

target nucleic acid hybrid and a second region which is a promoter for an RNA polymerase, the promoter oligonucleotide being modified to prevent the initiation of DNA synthesis therefrom;

a priming oligonucleotide which hybridizes to the 3 ′

-end of an RNA product transcribed from the promoter oligonucleotide;

target nucleic acid hybrid and primes the synthesis of a first DNA primer extension product complementary to the RNA product, wherein the RNA product comprises a base region complementary to the DNA target sequence, and wherein the priming oligonucleotide does not comprise RNA,

provided that the kit does not include a priming oligonucleotide which hybridizes to the target nucleic acid and primes the synthesis of a primer extension product complementary to the DNA target sequence, and

further provided that the kit does not include a restriction endonuclease capable of cleaving a double-stranded complex comprising the target nucleic acid.

32. The kit of claim 31, wherein the priming oligonucleotide has a cap hybridized to the 3′

-end thereof the cap comprising a base region which is complementary to at least 3 nucleotides at the 3′

-end of the priming oligonucleotide, wherein the 5′

-terminal base of the cap is complementary to the 3′

-terminal base of the priming oligonucleotide, and wherein the cap cannot be extended by a nucleic acid polymerase.

33. The kit of claim 32, wherein the cap is complementary to no more than 8 nucleotides at the 3′

-end of the priming oligonucleotide.

34. The kit of claim 32, wherein the cap prevents non-specific hybridization between the priming oligonucleotide and the promoter oligonucleotide when the cap is hybridized to the priming oligonucleotide.

35. The kit of claim 32, wherein the cap is a capping oligonucleotide modified to include a blocking moiety situated at its 3′

-terminus.

36. The kit of claim 32, wherein the 3′

-end of the cap is covalently attached to the 5′

-end of the priming oligonucleotide, and wherein the cap hybridizes to the 3′

-end of the priming oligonucleotide by forming a loop.

37. The kit of claim 36, wherein the cap is joined to the priming oligonucleotide via a linker region.

38. The kit of claim 37, wherein the linker region comprises at least 5 nucleotides.

39. The kit of claim 37, wherein the linker region comprises at least 5 a basic nucleotides.

40. The kit of claim 31, wherein the priming oligonucleotide does not include a non-hybridizing base region situated 5′

to the base region which hybridizes to the target sequence.

41. The kit of claim 40, wherein a 5′

-region of the priming oligonucleotide includes one or more modifications for increasing the binding affinity of the priming oligonucleotide for the target sequence, and wherein the modifications do not prevent the priming oligonucleotide from being extended in a primer extension reaction.

42. The kit of claim 41, wherein the modifications are spaced at least 15 bases from the 3′

-terminus of the priming oligonucleotide.

43. The kit of claim 31 further comprise a reverse transcriptase having an RNAse H activity.

44. The kit of claim 31 further comprising an enzyme having an RNAse H activity, wherein the enzyme is other than a reverse transcriptase.

45. The kit of claim 31 further comprising an extender oligonucleotide which hybridizes to the DNA target sequence or to the first DNA primer extension product 3′

to the promoter oligonucleotide, wherein the extender oligonucleotide is modified to prevent the initiation of DNA synthesis therefrom.

46. The kit of claim 31, wherein the promoter oligonucleotide further comprises an insertion sequence positioned between or adjacent to the first and second regions, and wherein the presence of the insertion sequence in the promoter oligonucleotide enhances the rate at which the RNA products are formed.

47. The kit of claim 46, wherein the insertion sequence comprises the nucleotide base sequence of SEQ ID NO:

1 or SEQ ID NO;

2.

48. The kit of claim 31, wherein the promoter oligonucleotide is modified to include a blocking moiety situated at its 3′

-terminus.

49. The kit of claim 48, wherein the first region of the promoter oligonucleotide is hybridized to an oligodeoxynucleotide, and wherein the first region comprises a 3′

-region having a sufficient number of contiguous ribonucleotides hybridized to the oligodeoxynucleotide such that the blocking moiety of the promoter oligonucleotide is released in the presence of an enzymatic activity capable of cleaving the region of ribonucleotides.

50. The kit of claim 49, wherein the promoter oligonucleotide comprises the oligodeoxynucleotide.

51. The kit of claim 48, wherein the blocking moiety of the promoter oligonucleotide comprises a substituent selected from the group consisting of:

a modified nucleotide, a nucleotide or a nucleotide sequence having a 3′

-to-5′

orientation, a 3′

alkyl group, a 3′

2′

-dideoxynucleotide, a 3′

cordycepin, a 3′

alkane-diol residue, a 3′

non-nucleotide moiety, a nucleotide sequence non-complementary to the target sequence, a nucleic acid binding protein, and mixtures thereof.

52. The kit of claim 51, wherein the blocking moiety comprises a nucleotide or a nucleotide sequence having a 3′

-to-5′

orientation or a 3′

-non-nucleotide moiety.

53. A kit for use in synthesizing multiple copies of an RNA target sequence, the kit comprising:

a priming oligonucleotide which hybridizes to the 3′

-end of the RNA target sequence and primes the synthesis of a first DNA primer extension product complementary to the RNA target sequence; and

a cap which hybridizes to a region at the 3′

-end of the priming oligonucleotide, wherein the 5′

-terminal base of the cap is complementary to the 3′

-terminal base of the priming oligonucleotide, and wherein the cap is modified to prevent the initiation of DNA synthesis therefrom.

54. The kit of claim 53, wherein the cap prevents non-specific hybridization between the priming oligonucleotide and any other oligonucleotide of the kit when the cap is hybridized to the priming oligonucleotide.

55. The kit of claim 53, wherein the cap is complementary to no more than 8 nucleotides at the 3′

-end of the priming oligonucleotide.

56. The kit of claim 55, wherein the cap is a capping oligonucleotide modified to include a blocking moiety situated at its 3′

-terminus.

57. The kit of claim 55, wherein the 3′

-end of the cap is covalently attached to the 5′

-end of the priming oligonucleotide, and wherein the cap hybridizes to the 3′

-end of the priming oligonucleotide by forming a loop.

58. The kit of claim 57, wherein the cap is joined to the priming oligonucleotide via a linker region.

59. The kit of claim 58, wherein the linker region comprises at least 5 nucleotides.

60. The kit of claim 58, wherein the linker region comprises at least 5 a basic nucleotides.

61. A composition comprising:

a promoter oligonucleotide having first and second regions, the first region comprising a 3 40 -portion containing a contiguous arrangement of ribonucleotides and a portion 5′

thereto that is capable of hybridizing to a DNA template, and the second region being a promoter for an RNA polymerase, wherein the first region is situated 3′

to the second region, and wherein the promoter oligonucleotide is modified to prevent the initiation of DNA synthesis therefrom; and

an oligodeoxynucleotide hybridized to the 3′

-portion of the first region, thereby forming an RNA;

DNA duplex.

62. The composition of claim 61, wherein the 3′

-portion of the first region contains a contiguous arrangement of at least 6 ribonucleotides.

63. The composition of claim 61, wherein the oligodeoxynucleotide is the same length as and fully complementary to the contiguous arrangement of ribonucleotides in the 3′

-portion of the first region.

64. The composition of claim 61, wherein the promoter oligonucleotide is modified to include a blocking moiety situated at its 3′

-terminus.

65. The composition of claim 64, wherein the blocking moiety of the promoter oligonucleotide comprises a substituent selected from the group consisting of:

a modified nucleotide, a nucleotide or a nucleotide sequence having a 3′

-to-5′

orientation, a 3′

alkyl group, a 3′

2′

-dideoxynucleotide, a 3′

cordycepin, a 3′

alkane-diol residue, a 3′

non-nucleotide moiety, a nucleotide sequence non-complementary to the target sequence, a nucleic acid binding protein, and mixtures thereof.

66. The composition of claim 65, wherein the blocking moiety comprises a nucleotide or a nucleotide sequence having a 3′

-to-5′

orientation or a 3′

-non-nucleotide moiety.

67. The composition of claim 61, wherein the oligodeoxynucleotide is joined to the promoter oligonucleotide by means of a linker.

68. A kit comprising the composition of claim 61 and an enzyme capable of cleaving the ribonucleotides of the RNA:

DNA duplex.

69. The kit of claim 68, wherein the enzyme is a reverse transcriptase having an RNAse H activity.

70. The kit of claim 68 further comprising a reverse transcriptase.

71. A method for making available a promoter oligonucleotide having a 3′

-end capable of being extended in the presence of a DNA polymerase, the method comprising;

(a) providing the composition of claim 61 to a reaction mixture;

(b) exposing the composition to an enzyme capable of cleaving the ribonucleotides of the RNA;

DNA duplex, thereby releasing a blocking moiety situated at the 3′

-end of the promoter oligonucleotide and making available the remaining portion of the first region for hybridization to the DNA template and extension of a 3′

-end thereof in the presence of a DNA polymerase.

72. The method of claim 71, wherein the 3′

-portion of the first region contains a contiguous arrangement of at least 6 ribonucleotides.

73. The method of claim 71, wherein the oligodeoxynucleotide is the same length as and fully complementary to the contiguous arrangement of ribonucleotides in the 3′

-portion of the first region.

74. The method of claim 73, wherein the blocking moiety of the promoter oligonucleotide comprises a substituent selected from the group consisting of:

a modified nucleotide, a nucleotide or a nucleotide sequence having a 3′

-to-5′

orientation, a 3′

alkyl group, a dideoxynucleotide, a 3′

cordycepin, a 3′

alkane-diol residue, a 3′

non-nucleotide moiety, a nucleotide sequence non-complementary to the target sequence, a nucleic acid binding protein, and mixtures thereof.

75. The method of claim 74, wherein the blocking moiety comprises a nucleotide or a nucleotide sequence having a 3′

-to-5′

orientation or a 3′

-non-nucleotide moiety.

76. The method of claim 71, wherein the oligodeoxynucleotide is joined to the promoter oligonucleotide by means of a linker.

77. The method of claim 71, wherein the enzyme is a reverse transcriptase having an RNAse H activity.

78. The method of claim 71, wherein the enzyme is other than a reverse transcriptase.

79. A kit for use in synthesizing multiple copies of a DNA target sequence contained within a target nucleic acid, the kit comprising:

a promoter oligonucleotide comprising a first region which hybridizes to a 3′

-region of the DNA target sequence present in a target nucleic acid to form a promoter oligonucleotide;

target nucleic acid hybrid and a second region which is a promoter for an RNA polymerase, the promoter oligonucleotide being modified to prevent the initiation of DNA synthesis therefrom;

a priming oligonucleotide which hybridizes to the 3 ′

-end of an RNA product transcribed from the promoter oligonucleotide;

target nucleic acid hybrid and primes the synthesis of a first DNA primer extension product complementary to the RNA product, wherein the RNA product comprises a base region complementary to the DNA target sequence; and

a cap hybridized to the 3′

-end of the priming oligonucleotide, the cap comprising a base region which is complementary to at least 3 nucleotides at the 3′

-end of the priming oligonucleotide, wherein the 5′

-terminal base of the cap is complementary to the 3′

-terminal base of the priming oligonucleotide, and wherein the cap cannot be extended by a nucleic acid polymerase,

provided that the kit does not include a priming oligonucleotide which hybridizes to the target nucleic acid and primes the synthesis of a primer extension product complementary to the DNA target sequence, and

further provided that the kit does not include a restriction endonuclease capable of cleaving a double-stranded complex comprising the target nucleic acid.

80. The kit of claim 79, wherein the cap is complementary to no more than 8 nucleotides at the 3′

-end of the priming oligonucleotide.

81. The kit of claim 79, wherein the cap prevents non-specific hybridization between the priming oligonucleotide and the promoter oligonucleotide when the cap is hybridized to the priming oligonucleotide.

82. The kit of claim 79, wherein the cap is a capping oligonucleotide modified to include a blocking moiety situated at its 3′

-terminus.

83. The kit of claim 79, wherein the 3′

-end of the cap is covalently attached to the 5′

-end of the priming oligonucleotide, and wherein the cap hybridizes to the 3′

-end of the priming oligonucleotide by forming a loop.

84. The kit of claim 83, wherein the cap is joined to the priming oligonucleotide via a linker region.

85. The kit of claim 84, wherein the linker region comprises at least 5 nucleotides.

86. The kit of claim 84, wherein the linker region comprises at least 5 a basic nucleotides.